Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Y-90 and SBRT in MSS Colorectal Cancer
NCT03802747Phase 1Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Aug 2019
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in colorectal cancer (CRC), sponsored by University of Colorado Denver. Planned start Aug 2019; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03802747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802747.